nodes	percent_of_prediction	percent_of_DWPC	metapath
Tamoxifen—CES1—Mycophenolate mofetil—psoriasis	0.0544	0.0771	CbGbCtD
Tamoxifen—CYP1A1—Clobetasol propionate—psoriasis	0.0454	0.0644	CbGbCtD
Tamoxifen—CYP2A6—Methoxsalen—psoriasis	0.0279	0.0396	CbGbCtD
Tamoxifen—CYP1A1—Methoxsalen—psoriasis	0.0239	0.0338	CbGbCtD
Tamoxifen—ABCB11—Cyclosporine—psoriasis	0.0237	0.0336	CbGbCtD
Tamoxifen—CYP19A1—Betamethasone—psoriasis	0.0217	0.0308	CbGbCtD
Tamoxifen—CYP2C8—Tazarotene—psoriasis	0.0214	0.0303	CbGbCtD
Tamoxifen—CYP3A5—Beclomethasone—psoriasis	0.0207	0.0293	CbGbCtD
Tamoxifen—CYP1A2—Clobetasol propionate—psoriasis	0.0203	0.0288	CbGbCtD
Tamoxifen—ABCC2—Mycophenolate mofetil—psoriasis	0.0164	0.0233	CbGbCtD
Tamoxifen—CYP1A1—Cholecalciferol—psoriasis	0.0158	0.0224	CbGbCtD
Tamoxifen—ABCB11—Dexamethasone—psoriasis	0.0156	0.0221	CbGbCtD
Tamoxifen—CYP1B1—Dexamethasone—psoriasis	0.0156	0.0221	CbGbCtD
Tamoxifen—ABCG2—Mycophenolate mofetil—psoriasis	0.0149	0.0211	CbGbCtD
Tamoxifen—CYP2A6—Prednisolone—psoriasis	0.0136	0.0193	CbGbCtD
Tamoxifen—CYP19A1—Dexamethasone—psoriasis	0.0126	0.0179	CbGbCtD
Tamoxifen—ABCC2—Cyclosporine—psoriasis	0.0124	0.0177	CbGbCtD
Tamoxifen—CYP2B6—Cholecalciferol—psoriasis	0.012	0.0171	CbGbCtD
Tamoxifen—ABCG2—Hydrocortisone—psoriasis	0.0119	0.0169	CbGbCtD
Tamoxifen—ABCG2—Cyclosporine—psoriasis	0.0113	0.016	CbGbCtD
Tamoxifen—CYP1A2—Methoxsalen—psoriasis	0.0107	0.0151	CbGbCtD
Tamoxifen—CYP2D6—Hydroxyurea—psoriasis	0.00961	0.0136	CbGbCtD
Tamoxifen—FMO3—sweat—psoriasis	0.00941	0.639	CbGeAlD
Tamoxifen—CYP2C8—Cholecalciferol—psoriasis	0.00912	0.0129	CbGbCtD
Tamoxifen—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0088	0.0125	CbGbCtD
Tamoxifen—CYP3A7—Hydrocortisone—psoriasis	0.0088	0.0125	CbGbCtD
Tamoxifen—CYP3A7—Cyclosporine—psoriasis	0.00831	0.0118	CbGbCtD
Tamoxifen—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.00831	0.0118	CbGbCtD
Tamoxifen—CYP3A5—Mycophenolate mofetil—psoriasis	0.00823	0.0117	CbGbCtD
Tamoxifen—ABCC2—Dexamethasone—psoriasis	0.0082	0.0116	CbGbCtD
Tamoxifen—CYP2A6—Dexamethasone—psoriasis	0.00801	0.0114	CbGbCtD
Tamoxifen—CYP2C8—Mycophenolate mofetil—psoriasis	0.00791	0.0112	CbGbCtD
Tamoxifen—CYP2C19—Cholecalciferol—psoriasis	0.00765	0.0109	CbGbCtD
Tamoxifen—ABCG2—Dexamethasone—psoriasis	0.00741	0.0105	CbGbCtD
Tamoxifen—CYP3A4—Calcitriol—psoriasis	0.00718	0.0102	CbGbCtD
Tamoxifen—CYP1A1—Dexamethasone—psoriasis	0.00684	0.0097	CbGbCtD
Tamoxifen—CYP3A5—Hydrocortisone—psoriasis	0.0066	0.00936	CbGbCtD
Tamoxifen—ABCC2—Methotrexate—psoriasis	0.00659	0.00934	CbGbCtD
Tamoxifen—CYP2C9—Cholecalciferol—psoriasis	0.00636	0.00902	CbGbCtD
Tamoxifen—CYP2C8—Hydrocortisone—psoriasis	0.00635	0.009	CbGbCtD
Tamoxifen—CYP3A5—Cyclosporine—psoriasis	0.00624	0.00884	CbGbCtD
Tamoxifen—CYP2C8—Cyclosporine—psoriasis	0.006	0.0085	CbGbCtD
Tamoxifen—ABCG2—Methotrexate—psoriasis	0.00596	0.00845	CbGbCtD
Tamoxifen—CYP2D6—Cholecalciferol—psoriasis	0.00582	0.00825	CbGbCtD
Tamoxifen—CYP3A4—Methoxsalen—psoriasis	0.00559	0.00792	CbGbCtD
Tamoxifen—CYP3A7—Dexamethasone—psoriasis	0.00547	0.00776	CbGbCtD
Tamoxifen—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.00547	0.00776	CbGbCtD
Tamoxifen—ABCB1—Mycophenolate mofetil—psoriasis	0.00535	0.00759	CbGbCtD
Tamoxifen—CYP2C19—Prednisone—psoriasis	0.00531	0.00752	CbGbCtD
Tamoxifen—CYP2E1—Dexamethasone—psoriasis	0.00528	0.00749	CbGbCtD
Tamoxifen—CYP2B6—Dexamethasone—psoriasis	0.00521	0.00739	CbGbCtD
Tamoxifen—CYP2C19—Cyclosporine—psoriasis	0.00503	0.00713	CbGbCtD
Tamoxifen—ABCB1—Betamethasone—psoriasis	0.00459	0.00651	CbGbCtD
Tamoxifen—ABCB1—Prednisolone—psoriasis	0.00453	0.00643	CbGbCtD
Tamoxifen—ABCB1—Hydrocortisone—psoriasis	0.0043	0.00609	CbGbCtD
Tamoxifen—ABCB1—Prednisone—psoriasis	0.00428	0.00607	CbGbCtD
Tamoxifen—CYP2C9—Cyclosporine—psoriasis	0.00418	0.00593	CbGbCtD
Tamoxifen—CYP3A5—Dexamethasone—psoriasis	0.00411	0.00582	CbGbCtD
Tamoxifen—ABCB1—Cyclosporine—psoriasis	0.00406	0.00575	CbGbCtD
Tamoxifen—CYP2C8—Dexamethasone—psoriasis	0.00395	0.0056	CbGbCtD
Tamoxifen—CYP2D6—Cyclosporine—psoriasis	0.00382	0.00542	CbGbCtD
Tamoxifen—CYP3A4—Cholecalciferol—psoriasis	0.0037	0.00525	CbGbCtD
Tamoxifen—CYP2C19—Dexamethasone—psoriasis	0.00331	0.0047	CbGbCtD
Tamoxifen—CYP3A4—Triamcinolone—psoriasis	0.00321	0.00455	CbGbCtD
Tamoxifen—CYP3A4—Mycophenolate mofetil—psoriasis	0.00321	0.00455	CbGbCtD
Tamoxifen—CYP2C9—Dexamethasone—psoriasis	0.00275	0.0039	CbGbCtD
Tamoxifen—CYP3A4—Betamethasone—psoriasis	0.00275	0.0039	CbGbCtD
Tamoxifen—CYP3A4—Prednisolone—psoriasis	0.00272	0.00385	CbGbCtD
Tamoxifen—ABCB1—Dexamethasone—psoriasis	0.00267	0.00379	CbGbCtD
Tamoxifen—CYP3A4—Hydrocortisone—psoriasis	0.00257	0.00365	CbGbCtD
Tamoxifen—CYP3A4—Prednisone—psoriasis	0.00256	0.00364	CbGbCtD
Tamoxifen—CYP2D6—Dexamethasone—psoriasis	0.00252	0.00357	CbGbCtD
Tamoxifen—CYP3A4—Cyclosporine—psoriasis	0.00243	0.00345	CbGbCtD
Tamoxifen—ABCB1—Methotrexate—psoriasis	0.00215	0.00305	CbGbCtD
Tamoxifen—CYP3A4—Dexamethasone—psoriasis	0.0016	0.00227	CbGbCtD
Tamoxifen—SULT1A1—tendon—psoriasis	0.000832	0.0565	CbGeAlD
Tamoxifen—DHCR7—skin of body—psoriasis	0.000777	0.0528	CbGeAlD
Tamoxifen—CYP1A1—skin epidermis—psoriasis	0.000772	0.0524	CbGeAlD
Tamoxifen—FMO1—tendon—psoriasis	0.000592	0.0402	CbGeAlD
Tamoxifen—ESRRA—tendon—psoriasis	0.000582	0.0395	CbGeAlD
Tamoxifen—SIGMAR1—Levonorgestrel—Hydrocortisone—psoriasis	0.000473	1	CbGdCrCtD
Tamoxifen—CYP1B1—skin of body—psoriasis	0.000338	0.023	CbGeAlD
Tamoxifen—SIGMAR1—tendon—psoriasis	0.000271	0.0184	CbGeAlD
Tamoxifen—ABCC2—tendon—psoriasis	0.000263	0.0179	CbGeAlD
Tamoxifen—CYP1B1—tendon—psoriasis	0.000258	0.0175	CbGeAlD
Tamoxifen—CYP1A1—skin of body—psoriasis	0.000239	0.0162	CbGeAlD
Tamoxifen—CYP2B6—skin of body—psoriasis	0.000232	0.0158	CbGeAlD
Tamoxifen—CYP2E1—tendon—psoriasis	0.000166	0.0113	CbGeAlD
Tamoxifen—Hypertension—Triamcinolone—psoriasis	7.23e-05	0.000365	CcSEcCtD
Tamoxifen—Infection—Hydrocortisone—psoriasis	7.21e-05	0.000364	CcSEcCtD
Tamoxifen—Insomnia—Mycophenolate mofetil—psoriasis	7.2e-05	0.000363	CcSEcCtD
Tamoxifen—Dyspepsia—Cyclosporine—psoriasis	7.19e-05	0.000363	CcSEcCtD
Tamoxifen—Hyperhidrosis—Prednisolone—psoriasis	7.18e-05	0.000362	CcSEcCtD
Tamoxifen—Nausea—Hydroxyurea—psoriasis	7.16e-05	0.000361	CcSEcCtD
Tamoxifen—Paraesthesia—Mycophenolate mofetil—psoriasis	7.15e-05	0.000361	CcSEcCtD
Tamoxifen—Pruritus—Mycophenolic acid—psoriasis	7.14e-05	0.00036	CcSEcCtD
Tamoxifen—Myalgia—Triamcinolone—psoriasis	7.13e-05	0.00036	CcSEcCtD
Tamoxifen—Pneumonia—Methotrexate—psoriasis	7.12e-05	0.000359	CcSEcCtD
Tamoxifen—Dyspnoea—Mycophenolate mofetil—psoriasis	7.1e-05	0.000358	CcSEcCtD
Tamoxifen—Decreased appetite—Cyclosporine—psoriasis	7.1e-05	0.000358	CcSEcCtD
Tamoxifen—Depression—Methotrexate—psoriasis	7.05e-05	0.000356	CcSEcCtD
Tamoxifen—Flushing—Prednisone—psoriasis	7.05e-05	0.000356	CcSEcCtD
Tamoxifen—Gastrointestinal disorder—Cyclosporine—psoriasis	7.05e-05	0.000356	CcSEcCtD
Tamoxifen—Discomfort—Triamcinolone—psoriasis	7.04e-05	0.000355	CcSEcCtD
Tamoxifen—Fatigue—Cyclosporine—psoriasis	7.04e-05	0.000355	CcSEcCtD
Tamoxifen—Hyperhidrosis—Hydrocortisone—psoriasis	7.02e-05	0.000354	CcSEcCtD
Tamoxifen—Stevens-Johnson syndrome—Methotrexate—psoriasis	7.01e-05	0.000354	CcSEcCtD
Tamoxifen—Dyspepsia—Mycophenolate mofetil—psoriasis	7.01e-05	0.000354	CcSEcCtD
Tamoxifen—Constipation—Cyclosporine—psoriasis	6.98e-05	0.000352	CcSEcCtD
Tamoxifen—Pain—Cyclosporine—psoriasis	6.98e-05	0.000352	CcSEcCtD
Tamoxifen—Dry mouth—Triamcinolone—psoriasis	6.97e-05	0.000352	CcSEcCtD
Tamoxifen—Angioedema—Betamethasone—psoriasis	6.94e-05	0.00035	CcSEcCtD
Tamoxifen—Angioedema—Dexamethasone—psoriasis	6.94e-05	0.00035	CcSEcCtD
Tamoxifen—Decreased appetite—Mycophenolate mofetil—psoriasis	6.92e-05	0.000349	CcSEcCtD
Tamoxifen—Anorexia—Hydrocortisone—psoriasis	6.92e-05	0.000349	CcSEcCtD
Tamoxifen—Diarrhoea—Mycophenolic acid—psoriasis	6.91e-05	0.000348	CcSEcCtD
Tamoxifen—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	6.88e-05	0.000347	CcSEcCtD
Tamoxifen—Oedema—Triamcinolone—psoriasis	6.83e-05	0.000345	CcSEcCtD
Tamoxifen—Constipation—Mycophenolate mofetil—psoriasis	6.81e-05	0.000344	CcSEcCtD
Tamoxifen—Pain—Mycophenolate mofetil—psoriasis	6.81e-05	0.000344	CcSEcCtD
Tamoxifen—Arrhythmia—Prednisone—psoriasis	6.79e-05	0.000342	CcSEcCtD
Tamoxifen—Infection—Triamcinolone—psoriasis	6.79e-05	0.000342	CcSEcCtD
Tamoxifen—Sweating—Methotrexate—psoriasis	6.78e-05	0.000342	CcSEcCtD
Tamoxifen—Insomnia—Prednisolone—psoriasis	6.72e-05	0.000339	CcSEcCtD
Tamoxifen—Alopecia—Prednisone—psoriasis	6.72e-05	0.000339	CcSEcCtD
Tamoxifen—Gastrointestinal pain—Cyclosporine—psoriasis	6.68e-05	0.000337	CcSEcCtD
Tamoxifen—Dizziness—Mycophenolic acid—psoriasis	6.67e-05	0.000337	CcSEcCtD
Tamoxifen—Paraesthesia—Prednisolone—psoriasis	6.67e-05	0.000337	CcSEcCtD
Tamoxifen—Erythema—Prednisone—psoriasis	6.62e-05	0.000334	CcSEcCtD
Tamoxifen—Musculoskeletal discomfort—Hydrocortisone—psoriasis	6.61e-05	0.000333	CcSEcCtD
Tamoxifen—Hyperhidrosis—Triamcinolone—psoriasis	6.61e-05	0.000333	CcSEcCtD
Tamoxifen—Insomnia—Hydrocortisone—psoriasis	6.56e-05	0.000331	CcSEcCtD
Tamoxifen—Hypertension—Betamethasone—psoriasis	6.56e-05	0.000331	CcSEcCtD
Tamoxifen—Hypertension—Dexamethasone—psoriasis	6.56e-05	0.000331	CcSEcCtD
Tamoxifen—Paraesthesia—Hydrocortisone—psoriasis	6.52e-05	0.000329	CcSEcCtD
Tamoxifen—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	6.51e-05	0.000329	CcSEcCtD
Tamoxifen—Urticaria—Cyclosporine—psoriasis	6.49e-05	0.000327	CcSEcCtD
Tamoxifen—Myalgia—Dexamethasone—psoriasis	6.47e-05	0.000326	CcSEcCtD
Tamoxifen—Myalgia—Betamethasone—psoriasis	6.47e-05	0.000326	CcSEcCtD
Tamoxifen—Abdominal pain—Cyclosporine—psoriasis	6.46e-05	0.000326	CcSEcCtD
Tamoxifen—Anxiety—Betamethasone—psoriasis	6.45e-05	0.000325	CcSEcCtD
Tamoxifen—Anxiety—Dexamethasone—psoriasis	6.45e-05	0.000325	CcSEcCtD
Tamoxifen—Vomiting—Mycophenolic acid—psoriasis	6.42e-05	0.000324	CcSEcCtD
Tamoxifen—Discomfort—Dexamethasone—psoriasis	6.39e-05	0.000322	CcSEcCtD
Tamoxifen—Discomfort—Betamethasone—psoriasis	6.39e-05	0.000322	CcSEcCtD
Tamoxifen—Dyspepsia—Hydrocortisone—psoriasis	6.39e-05	0.000322	CcSEcCtD
Tamoxifen—Haemoglobin—Methotrexate—psoriasis	6.38e-05	0.000322	CcSEcCtD
Tamoxifen—Rash—Mycophenolic acid—psoriasis	6.36e-05	0.000321	CcSEcCtD
Tamoxifen—Dermatitis—Mycophenolic acid—psoriasis	6.36e-05	0.000321	CcSEcCtD
Tamoxifen—Pain—Prednisolone—psoriasis	6.35e-05	0.00032	CcSEcCtD
Tamoxifen—Haemorrhage—Methotrexate—psoriasis	6.35e-05	0.00032	CcSEcCtD
Tamoxifen—Hepatitis—Methotrexate—psoriasis	6.35e-05	0.00032	CcSEcCtD
Tamoxifen—Urticaria—Mycophenolate mofetil—psoriasis	6.33e-05	0.000319	CcSEcCtD
Tamoxifen—Headache—Mycophenolic acid—psoriasis	6.32e-05	0.000319	CcSEcCtD
Tamoxifen—Decreased appetite—Hydrocortisone—psoriasis	6.31e-05	0.000318	CcSEcCtD
Tamoxifen—Pharyngitis—Methotrexate—psoriasis	6.3e-05	0.000318	CcSEcCtD
Tamoxifen—Abdominal pain—Mycophenolate mofetil—psoriasis	6.3e-05	0.000318	CcSEcCtD
Tamoxifen—Gastrointestinal disorder—Hydrocortisone—psoriasis	6.27e-05	0.000316	CcSEcCtD
Tamoxifen—Fatigue—Hydrocortisone—psoriasis	6.26e-05	0.000316	CcSEcCtD
Tamoxifen—Musculoskeletal discomfort—Triamcinolone—psoriasis	6.23e-05	0.000314	CcSEcCtD
Tamoxifen—Pain—Hydrocortisone—psoriasis	6.21e-05	0.000313	CcSEcCtD
Tamoxifen—Oedema—Betamethasone—psoriasis	6.2e-05	0.000313	CcSEcCtD
Tamoxifen—Oedema—Dexamethasone—psoriasis	6.2e-05	0.000313	CcSEcCtD
Tamoxifen—Insomnia—Triamcinolone—psoriasis	6.18e-05	0.000312	CcSEcCtD
Tamoxifen—Infection—Dexamethasone—psoriasis	6.16e-05	0.000311	CcSEcCtD
Tamoxifen—Infection—Betamethasone—psoriasis	6.16e-05	0.000311	CcSEcCtD
Tamoxifen—Paraesthesia—Triamcinolone—psoriasis	6.14e-05	0.000309	CcSEcCtD
Tamoxifen—Visual impairment—Methotrexate—psoriasis	6.12e-05	0.000309	CcSEcCtD
Tamoxifen—Anaemia—Prednisone—psoriasis	6.11e-05	0.000308	CcSEcCtD
Tamoxifen—Dyspnoea—Triamcinolone—psoriasis	6.09e-05	0.000307	CcSEcCtD
Tamoxifen—Thrombocytopenia—Dexamethasone—psoriasis	6.07e-05	0.000306	CcSEcCtD
Tamoxifen—Thrombocytopenia—Betamethasone—psoriasis	6.07e-05	0.000306	CcSEcCtD
Tamoxifen—Angioedema—Prednisone—psoriasis	6.05e-05	0.000305	CcSEcCtD
Tamoxifen—Hypersensitivity—Cyclosporine—psoriasis	6.02e-05	0.000303	CcSEcCtD
Tamoxifen—Dyspepsia—Triamcinolone—psoriasis	6.01e-05	0.000303	CcSEcCtD
Tamoxifen—Erythema multiforme—Methotrexate—psoriasis	6.01e-05	0.000303	CcSEcCtD
Tamoxifen—Nausea—Mycophenolic acid—psoriasis	6e-05	0.000302	CcSEcCtD
Tamoxifen—Hyperhidrosis—Betamethasone—psoriasis	5.99e-05	0.000302	CcSEcCtD
Tamoxifen—Hyperhidrosis—Dexamethasone—psoriasis	5.99e-05	0.000302	CcSEcCtD
Tamoxifen—Gastrointestinal pain—Hydrocortisone—psoriasis	5.93e-05	0.000299	CcSEcCtD
Tamoxifen—Anorexia—Dexamethasone—psoriasis	5.91e-05	0.000298	CcSEcCtD
Tamoxifen—Anorexia—Betamethasone—psoriasis	5.91e-05	0.000298	CcSEcCtD
Tamoxifen—Urticaria—Prednisolone—psoriasis	5.9e-05	0.000298	CcSEcCtD
Tamoxifen—Fatigue—Triamcinolone—psoriasis	5.89e-05	0.000297	CcSEcCtD
Tamoxifen—Hypersensitivity—Mycophenolate mofetil—psoriasis	5.87e-05	0.000296	CcSEcCtD
Tamoxifen—Asthenia—Cyclosporine—psoriasis	5.86e-05	0.000295	CcSEcCtD
Tamoxifen—Pain—Triamcinolone—psoriasis	5.84e-05	0.000295	CcSEcCtD
Tamoxifen—Pruritus—Cyclosporine—psoriasis	5.78e-05	0.000291	CcSEcCtD
Tamoxifen—Urticaria—Hydrocortisone—psoriasis	5.77e-05	0.000291	CcSEcCtD
Tamoxifen—Abdominal pain—Hydrocortisone—psoriasis	5.74e-05	0.000289	CcSEcCtD
Tamoxifen—Asthenia—Mycophenolate mofetil—psoriasis	5.72e-05	0.000288	CcSEcCtD
Tamoxifen—Hypertension—Prednisone—psoriasis	5.71e-05	0.000288	CcSEcCtD
Tamoxifen—Musculoskeletal discomfort—Betamethasone—psoriasis	5.65e-05	0.000285	CcSEcCtD
Tamoxifen—Musculoskeletal discomfort—Dexamethasone—psoriasis	5.65e-05	0.000285	CcSEcCtD
Tamoxifen—Pruritus—Mycophenolate mofetil—psoriasis	5.64e-05	0.000284	CcSEcCtD
Tamoxifen—Arthralgia—Prednisone—psoriasis	5.63e-05	0.000284	CcSEcCtD
Tamoxifen—Myalgia—Prednisone—psoriasis	5.63e-05	0.000284	CcSEcCtD
Tamoxifen—Anxiety—Prednisone—psoriasis	5.61e-05	0.000283	CcSEcCtD
Tamoxifen—Alopecia—Methotrexate—psoriasis	5.61e-05	0.000283	CcSEcCtD
Tamoxifen—Insomnia—Betamethasone—psoriasis	5.61e-05	0.000283	CcSEcCtD
Tamoxifen—Insomnia—Dexamethasone—psoriasis	5.61e-05	0.000283	CcSEcCtD
Tamoxifen—Diarrhoea—Cyclosporine—psoriasis	5.59e-05	0.000282	CcSEcCtD
Tamoxifen—Paraesthesia—Dexamethasone—psoriasis	5.57e-05	0.000281	CcSEcCtD
Tamoxifen—Paraesthesia—Betamethasone—psoriasis	5.57e-05	0.000281	CcSEcCtD
Tamoxifen—Discomfort—Prednisone—psoriasis	5.56e-05	0.000281	CcSEcCtD
Tamoxifen—Erythema—Methotrexate—psoriasis	5.53e-05	0.000279	CcSEcCtD
Tamoxifen—Hypersensitivity—Prednisolone—psoriasis	5.47e-05	0.000276	CcSEcCtD
Tamoxifen—Dyspepsia—Dexamethasone—psoriasis	5.46e-05	0.000275	CcSEcCtD
Tamoxifen—Dyspepsia—Betamethasone—psoriasis	5.46e-05	0.000275	CcSEcCtD
Tamoxifen—Diarrhoea—Mycophenolate mofetil—psoriasis	5.45e-05	0.000275	CcSEcCtD
Tamoxifen—Urticaria—Triamcinolone—psoriasis	5.43e-05	0.000274	CcSEcCtD
Tamoxifen—ABCB1—Allograft Rejection—IL4—psoriasis	5.42e-05	0.000666	CbGpPWpGaD
Tamoxifen—Dysgeusia—Methotrexate—psoriasis	5.41e-05	0.000273	CcSEcCtD
Tamoxifen—Dizziness—Cyclosporine—psoriasis	5.4e-05	0.000272	CcSEcCtD
Tamoxifen—Oedema—Prednisone—psoriasis	5.4e-05	0.000272	CcSEcCtD
Tamoxifen—Decreased appetite—Betamethasone—psoriasis	5.39e-05	0.000272	CcSEcCtD
Tamoxifen—Decreased appetite—Dexamethasone—psoriasis	5.39e-05	0.000272	CcSEcCtD
Tamoxifen—ESR2—SIDS Susceptibility Pathways—VEGFA—psoriasis	5.38e-05	0.000662	CbGpPWpGaD
Tamoxifen—ESR1—Leptin signaling pathway—NFKB1—psoriasis	5.37e-05	0.00066	CbGpPWpGaD
Tamoxifen—Infection—Prednisone—psoriasis	5.36e-05	0.000271	CcSEcCtD
Tamoxifen—Gastrointestinal disorder—Betamethasone—psoriasis	5.35e-05	0.00027	CcSEcCtD
Tamoxifen—Gastrointestinal disorder—Dexamethasone—psoriasis	5.35e-05	0.00027	CcSEcCtD
Tamoxifen—Back pain—Methotrexate—psoriasis	5.35e-05	0.00027	CcSEcCtD
Tamoxifen—Hypersensitivity—Hydrocortisone—psoriasis	5.35e-05	0.00027	CcSEcCtD
Tamoxifen—Fatigue—Dexamethasone—psoriasis	5.35e-05	0.00027	CcSEcCtD
Tamoxifen—Fatigue—Betamethasone—psoriasis	5.35e-05	0.00027	CcSEcCtD
Tamoxifen—Pain—Dexamethasone—psoriasis	5.3e-05	0.000267	CcSEcCtD
Tamoxifen—Pain—Betamethasone—psoriasis	5.3e-05	0.000267	CcSEcCtD
Tamoxifen—ABCB1—Allograft Rejection—HLA-B—psoriasis	5.3e-05	0.000652	CbGpPWpGaD
Tamoxifen—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	5.29e-05	0.000651	CbGpPWpGaD
Tamoxifen—ABCG2—HIF-1-alpha transcription factor network—VEGFA—psoriasis	5.28e-05	0.00065	CbGpPWpGaD
Tamoxifen—Dizziness—Mycophenolate mofetil—psoriasis	5.27e-05	0.000266	CcSEcCtD
Tamoxifen—ESR2—Generic Transcription Pathway—VDR—psoriasis	5.26e-05	0.000647	CbGpPWpGaD
Tamoxifen—CYP1A1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	5.26e-05	0.000647	CbGpPWpGaD
Tamoxifen—ESR1—Regulation of nuclear SMAD2/3 signaling—JUN—psoriasis	5.24e-05	0.000645	CbGpPWpGaD
Tamoxifen—ESR2—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	5.23e-05	0.000644	CbGpPWpGaD
Tamoxifen—Hyperhidrosis—Prednisone—psoriasis	5.22e-05	0.000263	CcSEcCtD
Tamoxifen—Asthenia—Hydrocortisone—psoriasis	5.21e-05	0.000263	CcSEcCtD
Tamoxifen—Vomiting—Cyclosporine—psoriasis	5.19e-05	0.000262	CcSEcCtD
Tamoxifen—ESRRA—Metabolism—CARM1—psoriasis	5.18e-05	0.000638	CbGpPWpGaD
Tamoxifen—Rash—Cyclosporine—psoriasis	5.15e-05	0.00026	CcSEcCtD
Tamoxifen—Anorexia—Prednisone—psoriasis	5.15e-05	0.00026	CcSEcCtD
Tamoxifen—Dermatitis—Cyclosporine—psoriasis	5.14e-05	0.000259	CcSEcCtD
Tamoxifen—Pruritus—Hydrocortisone—psoriasis	5.13e-05	0.000259	CcSEcCtD
Tamoxifen—Headache—Cyclosporine—psoriasis	5.12e-05	0.000258	CcSEcCtD
Tamoxifen—Anaemia—Methotrexate—psoriasis	5.11e-05	0.000258	CcSEcCtD
Tamoxifen—Gastrointestinal pain—Dexamethasone—psoriasis	5.07e-05	0.000256	CcSEcCtD
Tamoxifen—Gastrointestinal pain—Betamethasone—psoriasis	5.07e-05	0.000256	CcSEcCtD
Tamoxifen—Vomiting—Mycophenolate mofetil—psoriasis	5.06e-05	0.000255	CcSEcCtD
Tamoxifen—ABCB11—Metabolism—CYP2S1—psoriasis	5.04e-05	0.00062	CbGpPWpGaD
Tamoxifen—ESR2—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	5.04e-05	0.00062	CbGpPWpGaD
Tamoxifen—Hypersensitivity—Triamcinolone—psoriasis	5.03e-05	0.000254	CcSEcCtD
Tamoxifen—Rash—Mycophenolate mofetil—psoriasis	5.02e-05	0.000253	CcSEcCtD
Tamoxifen—Dermatitis—Mycophenolate mofetil—psoriasis	5.02e-05	0.000253	CcSEcCtD
Tamoxifen—Headache—Mycophenolate mofetil—psoriasis	4.99e-05	0.000252	CcSEcCtD
Tamoxifen—Diarrhoea—Hydrocortisone—psoriasis	4.97e-05	0.00025	CcSEcCtD
Tamoxifen—Leukopenia—Methotrexate—psoriasis	4.95e-05	0.00025	CcSEcCtD
Tamoxifen—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	4.93e-05	0.000607	CbGpPWpGaD
Tamoxifen—Urticaria—Betamethasone—psoriasis	4.93e-05	0.000248	CcSEcCtD
Tamoxifen—Urticaria—Dexamethasone—psoriasis	4.93e-05	0.000248	CcSEcCtD
Tamoxifen—Musculoskeletal discomfort—Prednisone—psoriasis	4.92e-05	0.000248	CcSEcCtD
Tamoxifen—Dizziness—Prednisolone—psoriasis	4.91e-05	0.000248	CcSEcCtD
Tamoxifen—ABCB1—Allograft Rejection—HLA-A—psoriasis	4.91e-05	0.000604	CbGpPWpGaD
Tamoxifen—Asthenia—Triamcinolone—psoriasis	4.9e-05	0.000247	CcSEcCtD
Tamoxifen—Abdominal pain—Dexamethasone—psoriasis	4.9e-05	0.000247	CcSEcCtD
Tamoxifen—Abdominal pain—Betamethasone—psoriasis	4.9e-05	0.000247	CcSEcCtD
Tamoxifen—Insomnia—Prednisone—psoriasis	4.88e-05	0.000246	CcSEcCtD
Tamoxifen—Nausea—Cyclosporine—psoriasis	4.85e-05	0.000245	CcSEcCtD
Tamoxifen—Paraesthesia—Prednisone—psoriasis	4.85e-05	0.000245	CcSEcCtD
Tamoxifen—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	4.85e-05	0.000597	CbGpPWpGaD
Tamoxifen—ESRRA—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.84e-05	0.000596	CbGpPWpGaD
Tamoxifen—Pruritus—Triamcinolone—psoriasis	4.83e-05	0.000244	CcSEcCtD
Tamoxifen—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.83e-05	0.000594	CbGpPWpGaD
Tamoxifen—Cough—Methotrexate—psoriasis	4.82e-05	0.000243	CcSEcCtD
Tamoxifen—ESR1—Leptin signaling pathway—STAT3—psoriasis	4.82e-05	0.000594	CbGpPWpGaD
Tamoxifen—Dizziness—Hydrocortisone—psoriasis	4.8e-05	0.000242	CcSEcCtD
Tamoxifen—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	4.77e-05	0.000587	CbGpPWpGaD
Tamoxifen—Dyspepsia—Prednisone—psoriasis	4.75e-05	0.00024	CcSEcCtD
Tamoxifen—ESR1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	4.74e-05	0.000583	CbGpPWpGaD
Tamoxifen—Nausea—Mycophenolate mofetil—psoriasis	4.73e-05	0.000239	CcSEcCtD
Tamoxifen—Myalgia—Methotrexate—psoriasis	4.71e-05	0.000237	CcSEcCtD
Tamoxifen—Chest pain—Methotrexate—psoriasis	4.71e-05	0.000237	CcSEcCtD
Tamoxifen—Arthralgia—Methotrexate—psoriasis	4.71e-05	0.000237	CcSEcCtD
Tamoxifen—Decreased appetite—Prednisone—psoriasis	4.69e-05	0.000237	CcSEcCtD
Tamoxifen—Rash—Prednisolone—psoriasis	4.69e-05	0.000236	CcSEcCtD
Tamoxifen—Dermatitis—Prednisolone—psoriasis	4.68e-05	0.000236	CcSEcCtD
Tamoxifen—Fatigue—Prednisone—psoriasis	4.66e-05	0.000235	CcSEcCtD
Tamoxifen—Headache—Prednisolone—psoriasis	4.65e-05	0.000235	CcSEcCtD
Tamoxifen—Discomfort—Methotrexate—psoriasis	4.65e-05	0.000235	CcSEcCtD
Tamoxifen—Constipation—Prednisone—psoriasis	4.62e-05	0.000233	CcSEcCtD
Tamoxifen—Vomiting—Hydrocortisone—psoriasis	4.61e-05	0.000233	CcSEcCtD
Tamoxifen—ESR2—SIDS Susceptibility Pathways—TNF—psoriasis	4.61e-05	0.000567	CbGpPWpGaD
Tamoxifen—Rash—Hydrocortisone—psoriasis	4.58e-05	0.000231	CcSEcCtD
Tamoxifen—ESR2—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	4.57e-05	0.000563	CbGpPWpGaD
Tamoxifen—Dermatitis—Hydrocortisone—psoriasis	4.57e-05	0.000231	CcSEcCtD
Tamoxifen—Headache—Hydrocortisone—psoriasis	4.55e-05	0.000229	CcSEcCtD
Tamoxifen—Dizziness—Triamcinolone—psoriasis	4.52e-05	0.000228	CcSEcCtD
Tamoxifen—FMO3—SIDS Susceptibility Pathways—IL6—psoriasis	4.49e-05	0.000553	CbGpPWpGaD
Tamoxifen—Infection—Methotrexate—psoriasis	4.48e-05	0.000226	CcSEcCtD
Tamoxifen—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	4.48e-05	0.000552	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism—NDUFA5—psoriasis	4.47e-05	0.00055	CbGpPWpGaD
Tamoxifen—Asthenia—Dexamethasone—psoriasis	4.45e-05	0.000224	CcSEcCtD
Tamoxifen—Asthenia—Betamethasone—psoriasis	4.45e-05	0.000224	CcSEcCtD
Tamoxifen—ESR1—Generic Transcription Pathway—CARM1—psoriasis	4.44e-05	0.000546	CbGpPWpGaD
Tamoxifen—Thrombocytopenia—Methotrexate—psoriasis	4.42e-05	0.000223	CcSEcCtD
Tamoxifen—Gastrointestinal pain—Prednisone—psoriasis	4.42e-05	0.000223	CcSEcCtD
Tamoxifen—Nausea—Prednisolone—psoriasis	4.41e-05	0.000223	CcSEcCtD
Tamoxifen—Pruritus—Dexamethasone—psoriasis	4.39e-05	0.000221	CcSEcCtD
Tamoxifen—Pruritus—Betamethasone—psoriasis	4.39e-05	0.000221	CcSEcCtD
Tamoxifen—Hyperhidrosis—Methotrexate—psoriasis	4.36e-05	0.00022	CcSEcCtD
Tamoxifen—Vomiting—Triamcinolone—psoriasis	4.34e-05	0.000219	CcSEcCtD
Tamoxifen—Nausea—Hydrocortisone—psoriasis	4.31e-05	0.000217	CcSEcCtD
Tamoxifen—Rash—Triamcinolone—psoriasis	4.31e-05	0.000217	CcSEcCtD
Tamoxifen—CYP1B1—Metabolism—NDUFA5—psoriasis	4.31e-05	0.00053	CbGpPWpGaD
Tamoxifen—Dermatitis—Triamcinolone—psoriasis	4.3e-05	0.000217	CcSEcCtD
Tamoxifen—Anorexia—Methotrexate—psoriasis	4.3e-05	0.000217	CcSEcCtD
Tamoxifen—Urticaria—Prednisone—psoriasis	4.29e-05	0.000216	CcSEcCtD
Tamoxifen—Headache—Triamcinolone—psoriasis	4.28e-05	0.000216	CcSEcCtD
Tamoxifen—Abdominal pain—Prednisone—psoriasis	4.27e-05	0.000215	CcSEcCtD
Tamoxifen—Diarrhoea—Betamethasone—psoriasis	4.24e-05	0.000214	CcSEcCtD
Tamoxifen—Diarrhoea—Dexamethasone—psoriasis	4.24e-05	0.000214	CcSEcCtD
Tamoxifen—ESR2—Gene Expression—CARM1—psoriasis	4.24e-05	0.000522	CbGpPWpGaD
Tamoxifen—DHCR7—Metabolism—CAT—psoriasis	4.2e-05	0.000517	CbGpPWpGaD
Tamoxifen—ABCC2—Transmembrane transport of small molecules—CP—psoriasis	4.19e-05	0.000515	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.17e-05	0.000513	CbGpPWpGaD
Tamoxifen—SULT1A1—Metabolism—CAT—psoriasis	4.13e-05	0.000508	CbGpPWpGaD
Tamoxifen—Musculoskeletal discomfort—Methotrexate—psoriasis	4.11e-05	0.000207	CcSEcCtD
Tamoxifen—Dizziness—Dexamethasone—psoriasis	4.1e-05	0.000207	CcSEcCtD
Tamoxifen—Dizziness—Betamethasone—psoriasis	4.1e-05	0.000207	CcSEcCtD
Tamoxifen—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	4.09e-05	0.000503	CbGpPWpGaD
Tamoxifen—CYP1A1—Aryl Hydrocarbon Receptor—TNF—psoriasis	4.09e-05	0.000503	CbGpPWpGaD
Tamoxifen—ESR1—ATF-2 transcription factor network—IL6—psoriasis	4.08e-05	0.000502	CbGpPWpGaD
Tamoxifen—Insomnia—Methotrexate—psoriasis	4.08e-05	0.000206	CcSEcCtD
Tamoxifen—Nausea—Triamcinolone—psoriasis	4.06e-05	0.000205	CcSEcCtD
Tamoxifen—Paraesthesia—Methotrexate—psoriasis	4.05e-05	0.000204	CcSEcCtD
Tamoxifen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	4.03e-05	0.000496	CbGpPWpGaD
Tamoxifen—Dyspnoea—Methotrexate—psoriasis	4.02e-05	0.000203	CcSEcCtD
Tamoxifen—CYP1B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.02e-05	0.000494	CbGpPWpGaD
Tamoxifen—ABCC2—Transmembrane transport of small molecules—CARM1—psoriasis	3.99e-05	0.000492	CbGpPWpGaD
Tamoxifen—EBP—Metabolism—CAT—psoriasis	3.99e-05	0.000491	CbGpPWpGaD
Tamoxifen—FMO3—Metabolism—CARM1—psoriasis	3.98e-05	0.00049	CbGpPWpGaD
Tamoxifen—ESR1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.98e-05	0.00049	CbGpPWpGaD
Tamoxifen—ESRRA—Gene Expression—VDR—psoriasis	3.98e-05	0.00049	CbGpPWpGaD
Tamoxifen—Hypersensitivity—Prednisone—psoriasis	3.98e-05	0.000201	CcSEcCtD
Tamoxifen—Dyspepsia—Methotrexate—psoriasis	3.97e-05	0.0002	CcSEcCtD
Tamoxifen—Vomiting—Dexamethasone—psoriasis	3.94e-05	0.000199	CcSEcCtD
Tamoxifen—Vomiting—Betamethasone—psoriasis	3.94e-05	0.000199	CcSEcCtD
Tamoxifen—Decreased appetite—Methotrexate—psoriasis	3.92e-05	0.000198	CcSEcCtD
Tamoxifen—ESR2—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	3.92e-05	0.000482	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—NDUFA5—psoriasis	3.92e-05	0.000482	CbGpPWpGaD
Tamoxifen—ESR1—Signaling by ERBB4—TYK2—psoriasis	3.91e-05	0.000482	CbGpPWpGaD
Tamoxifen—Rash—Betamethasone—psoriasis	3.91e-05	0.000197	CcSEcCtD
Tamoxifen—Rash—Dexamethasone—psoriasis	3.91e-05	0.000197	CcSEcCtD
Tamoxifen—Dermatitis—Dexamethasone—psoriasis	3.91e-05	0.000197	CcSEcCtD
Tamoxifen—Dermatitis—Betamethasone—psoriasis	3.91e-05	0.000197	CcSEcCtD
Tamoxifen—Gastrointestinal disorder—Methotrexate—psoriasis	3.9e-05	0.000196	CcSEcCtD
Tamoxifen—Fatigue—Methotrexate—psoriasis	3.89e-05	0.000196	CcSEcCtD
Tamoxifen—ESR1—AP-1 transcription factor network—TP53—psoriasis	3.89e-05	0.000479	CbGpPWpGaD
Tamoxifen—Headache—Dexamethasone—psoriasis	3.88e-05	0.000196	CcSEcCtD
Tamoxifen—Headache—Betamethasone—psoriasis	3.88e-05	0.000196	CcSEcCtD
Tamoxifen—CYP3A7—Metabolism—NDUFA5—psoriasis	3.88e-05	0.000478	CbGpPWpGaD
Tamoxifen—Asthenia—Prednisone—psoriasis	3.87e-05	0.000195	CcSEcCtD
Tamoxifen—Pain—Methotrexate—psoriasis	3.86e-05	0.000195	CcSEcCtD
Tamoxifen—CYP1A1—PPARA activates gene expression—PPARG—psoriasis	3.83e-05	0.000472	CbGpPWpGaD
Tamoxifen—Pruritus—Prednisone—psoriasis	3.82e-05	0.000193	CcSEcCtD
Tamoxifen—CYP19A1—Metabolism—CYP2S1—psoriasis	3.8e-05	0.000468	CbGpPWpGaD
Tamoxifen—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	3.75e-05	0.000462	CbGpPWpGaD
Tamoxifen—ESR2—SIDS Susceptibility Pathways—IL6—psoriasis	3.72e-05	0.000458	CbGpPWpGaD
Tamoxifen—Diarrhoea—Prednisone—psoriasis	3.69e-05	0.000186	CcSEcCtD
Tamoxifen—Gastrointestinal pain—Methotrexate—psoriasis	3.69e-05	0.000186	CcSEcCtD
Tamoxifen—Nausea—Betamethasone—psoriasis	3.68e-05	0.000186	CcSEcCtD
Tamoxifen—Nausea—Dexamethasone—psoriasis	3.68e-05	0.000186	CcSEcCtD
Tamoxifen—ESR2—Generic Transcription Pathway—PPARG—psoriasis	3.67e-05	0.000451	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism—CYP2S1—psoriasis	3.66e-05	0.000451	CbGpPWpGaD
Tamoxifen—ABCG2—Transmembrane transport of small molecules—CP—psoriasis	3.64e-05	0.000448	CbGpPWpGaD
Tamoxifen—Urticaria—Methotrexate—psoriasis	3.58e-05	0.000181	CcSEcCtD
Tamoxifen—Dizziness—Prednisone—psoriasis	3.57e-05	0.00018	CcSEcCtD
Tamoxifen—Abdominal pain—Methotrexate—psoriasis	3.57e-05	0.00018	CcSEcCtD
Tamoxifen—ESR1—AP-1 transcription factor network—IL6—psoriasis	3.56e-05	0.000438	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—NDUFA5—psoriasis	3.56e-05	0.000438	CbGpPWpGaD
Tamoxifen—CYP19A1—Integrated Breast Cancer Pathway—JUN—psoriasis	3.56e-05	0.000438	CbGpPWpGaD
Tamoxifen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	3.48e-05	0.000429	CbGpPWpGaD
Tamoxifen—ABCG2—Transmembrane transport of small molecules—CARM1—psoriasis	3.47e-05	0.000427	CbGpPWpGaD
Tamoxifen—ESR2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	3.46e-05	0.000425	CbGpPWpGaD
Tamoxifen—Vomiting—Prednisone—psoriasis	3.43e-05	0.000173	CcSEcCtD
Tamoxifen—FMO1—Metabolism—CAT—psoriasis	3.43e-05	0.000422	CbGpPWpGaD
Tamoxifen—CYP19A1—Integrated Breast Cancer Pathway—NFKB1—psoriasis	3.43e-05	0.000421	CbGpPWpGaD
Tamoxifen—Rash—Prednisone—psoriasis	3.4e-05	0.000172	CcSEcCtD
Tamoxifen—Dermatitis—Prednisone—psoriasis	3.4e-05	0.000172	CcSEcCtD
Tamoxifen—Headache—Prednisone—psoriasis	3.38e-05	0.000171	CcSEcCtD
Tamoxifen—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	3.35e-05	0.000412	CbGpPWpGaD
Tamoxifen—UGT1A4—Metabolism—CARM1—psoriasis	3.34e-05	0.000411	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—CYP2S1—psoriasis	3.33e-05	0.00041	CbGpPWpGaD
Tamoxifen—Hypersensitivity—Methotrexate—psoriasis	3.32e-05	0.000168	CcSEcCtD
Tamoxifen—CYP3A7—Metabolism—CYP2S1—psoriasis	3.3e-05	0.000406	CbGpPWpGaD
Tamoxifen—ABCB1—Allograft Rejection—IFNG—psoriasis	3.27e-05	0.000403	CbGpPWpGaD
Tamoxifen—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	3.27e-05	0.000402	CbGpPWpGaD
Tamoxifen—DHCR7—Metabolism—APOE—psoriasis	3.27e-05	0.000402	CbGpPWpGaD
Tamoxifen—Asthenia—Methotrexate—psoriasis	3.24e-05	0.000163	CcSEcCtD
Tamoxifen—Nausea—Prednisone—psoriasis	3.21e-05	0.000162	CcSEcCtD
Tamoxifen—SULT1A1—Metabolism—APOE—psoriasis	3.21e-05	0.000395	CbGpPWpGaD
Tamoxifen—Pruritus—Methotrexate—psoriasis	3.19e-05	0.000161	CcSEcCtD
Tamoxifen—ESRRA—Metabolism—CAT—psoriasis	3.19e-05	0.000392	CbGpPWpGaD
Tamoxifen—ESR1—Integrated Breast Cancer Pathway—JUN—psoriasis	3.19e-05	0.000392	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—HCAR2—psoriasis	3.15e-05	0.000387	CbGpPWpGaD
Tamoxifen—CYP19A1—Integrated Breast Cancer Pathway—VEGFA—psoriasis	3.11e-05	0.000383	CbGpPWpGaD
Tamoxifen—EBP—Metabolism—APOE—psoriasis	3.1e-05	0.000381	CbGpPWpGaD
Tamoxifen—Diarrhoea—Methotrexate—psoriasis	3.09e-05	0.000156	CcSEcCtD
Tamoxifen—ESR1—Integrated Breast Cancer Pathway—NFKB1—psoriasis	3.07e-05	0.000377	CbGpPWpGaD
Tamoxifen—ABCB1—Allograft Rejection—CXCL8—psoriasis	3.04e-05	0.000375	CbGpPWpGaD
Tamoxifen—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	3.04e-05	0.000374	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—CYP2S1—psoriasis	3.03e-05	0.000372	CbGpPWpGaD
Tamoxifen—Dizziness—Methotrexate—psoriasis	2.98e-05	0.000151	CcSEcCtD
Tamoxifen—CYP2B6—Metabolism—NDUFA5—psoriasis	2.87e-05	0.000353	CbGpPWpGaD
Tamoxifen—Vomiting—Methotrexate—psoriasis	2.87e-05	0.000145	CcSEcCtD
Tamoxifen—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	2.85e-05	0.000351	CbGpPWpGaD
Tamoxifen—DHCR7—Metabolism—PPARG—psoriasis	2.85e-05	0.00035	CbGpPWpGaD
Tamoxifen—Rash—Methotrexate—psoriasis	2.85e-05	0.000144	CcSEcCtD
Tamoxifen—Dermatitis—Methotrexate—psoriasis	2.84e-05	0.000143	CcSEcCtD
Tamoxifen—Headache—Methotrexate—psoriasis	2.83e-05	0.000143	CcSEcCtD
Tamoxifen—CYP2E1—Metabolism—NDUFA5—psoriasis	2.81e-05	0.000346	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—NDUFA5—psoriasis	2.81e-05	0.000345	CbGpPWpGaD
Tamoxifen—SULT1A1—Metabolism—PPARG—psoriasis	2.79e-05	0.000344	CbGpPWpGaD
Tamoxifen—ESR1—Integrated Breast Cancer Pathway—VEGFA—psoriasis	2.78e-05	0.000342	CbGpPWpGaD
Tamoxifen—ESRRA—Gene Expression—PPARG—psoriasis	2.77e-05	0.000341	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—TAGAP—psoriasis	2.73e-05	0.000336	CbGpPWpGaD
Tamoxifen—EBP—Metabolism—PPARG—psoriasis	2.7e-05	0.000332	CbGpPWpGaD
Tamoxifen—Nausea—Methotrexate—psoriasis	2.68e-05	0.000135	CcSEcCtD
Tamoxifen—FMO1—Metabolism—APOE—psoriasis	2.66e-05	0.000328	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—NDUFA5—psoriasis	2.65e-05	0.000326	CbGpPWpGaD
Tamoxifen—ESR1—Generic Transcription Pathway—VDR—psoriasis	2.65e-05	0.000326	CbGpPWpGaD
Tamoxifen—ABCB11—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.64e-05	0.000325	CbGpPWpGaD
Tamoxifen—ESR1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.64e-05	0.000325	CbGpPWpGaD
Tamoxifen—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.61e-05	0.000321	CbGpPWpGaD
Tamoxifen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.61e-05	0.000321	CbGpPWpGaD
Tamoxifen—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	2.58e-05	0.000318	CbGpPWpGaD
Tamoxifen—ESR1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.54e-05	0.000313	CbGpPWpGaD
Tamoxifen—ESR2—Gene Expression—VDR—psoriasis	2.53e-05	0.000312	CbGpPWpGaD
Tamoxifen—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	2.51e-05	0.000309	CbGpPWpGaD
Tamoxifen—ESRRA—Metabolism—APOE—psoriasis	2.48e-05	0.000305	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.47e-05	0.000304	CbGpPWpGaD
Tamoxifen—ABCB1—Allograft Rejection—VEGFA—psoriasis	2.47e-05	0.000304	CbGpPWpGaD
Tamoxifen—ABCB11—Metabolism—CARM1—psoriasis	2.46e-05	0.000303	CbGpPWpGaD
Tamoxifen—FMO3—Metabolism—CAT—psoriasis	2.45e-05	0.000302	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—CYP2S1—psoriasis	2.44e-05	0.000301	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—NDUFA5—psoriasis	2.43e-05	0.000299	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—CYP2S1—psoriasis	2.39e-05	0.000294	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—CYP2S1—psoriasis	2.39e-05	0.000294	CbGpPWpGaD
Tamoxifen—CYP19A1—Integrated Breast Cancer Pathway—TP53—psoriasis	2.35e-05	0.000289	CbGpPWpGaD
Tamoxifen—FMO1—Metabolism—PPARG—psoriasis	2.32e-05	0.000285	CbGpPWpGaD
Tamoxifen—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2.31e-05	0.000284	CbGpPWpGaD
Tamoxifen—ABCB11—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.3e-05	0.000283	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.27e-05	0.000279	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—CYP2S1—psoriasis	2.26e-05	0.000278	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—NDUFA5—psoriasis	2.17e-05	0.000267	CbGpPWpGaD
Tamoxifen—ESRRA—Metabolism—PPARG—psoriasis	2.16e-05	0.000265	CbGpPWpGaD
Tamoxifen—ESR1—Gene Expression—CARM1—psoriasis	2.14e-05	0.000263	CbGpPWpGaD
Tamoxifen—ABCB1—Allograft Rejection—TNF—psoriasis	2.12e-05	0.000261	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—NDUFA5—psoriasis	2.12e-05	0.000261	CbGpPWpGaD
Tamoxifen—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.11e-05	0.000259	CbGpPWpGaD
Tamoxifen—ESR1—Integrated Breast Cancer Pathway—TP53—psoriasis	2.1e-05	0.000259	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—CYP2S1—psoriasis	2.07e-05	0.000254	CbGpPWpGaD
Tamoxifen—UGT1A4—Metabolism—CAT—psoriasis	2.05e-05	0.000253	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.02e-05	0.000249	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—NDUFA5—psoriasis	2e-05	0.000246	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.99e-05	0.000245	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—NDUFA5—psoriasis	1.98e-05	0.000244	CbGpPWpGaD
Tamoxifen—ESR1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.98e-05	0.000243	CbGpPWpGaD
Tamoxifen—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	1.97e-05	0.000242	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.92e-05	0.000236	CbGpPWpGaD
Tamoxifen—ESR1—Signaling by ERBB4—IL6—psoriasis	1.91e-05	0.000236	CbGpPWpGaD
Tamoxifen—FMO3—Metabolism—APOE—psoriasis	1.9e-05	0.000234	CbGpPWpGaD
Tamoxifen—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	1.88e-05	0.000231	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism—CARM1—psoriasis	1.86e-05	0.000229	CbGpPWpGaD
Tamoxifen—ESR1—Generic Transcription Pathway—PPARG—psoriasis	1.85e-05	0.000227	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—CYP2S1—psoriasis	1.85e-05	0.000227	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.85e-05	0.000227	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—CYP2S1—psoriasis	1.8e-05	0.000222	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism—CARM1—psoriasis	1.79e-05	0.00022	CbGpPWpGaD
Tamoxifen—ESR2—Gene Expression—PPARG—psoriasis	1.77e-05	0.000217	CbGpPWpGaD
Tamoxifen—ESR1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.74e-05	0.000214	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.74e-05	0.000214	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—CYP2S1—psoriasis	1.7e-05	0.000209	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—NDUFA5—psoriasis	1.69e-05	0.000208	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—CYP2S1—psoriasis	1.68e-05	0.000207	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.67e-05	0.000206	CbGpPWpGaD
Tamoxifen—FMO3—Metabolism—PPARG—psoriasis	1.66e-05	0.000204	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—CCL20—psoriasis	1.63e-05	0.000201	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—CARM1—psoriasis	1.63e-05	0.0002	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—CARM1—psoriasis	1.61e-05	0.000198	CbGpPWpGaD
Tamoxifen—UGT1A4—Metabolism—APOE—psoriasis	1.6e-05	0.000196	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.58e-05	0.000194	CbGpPWpGaD
Tamoxifen—ABCB11—Metabolism—CAT—psoriasis	1.51e-05	0.000186	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—CARM1—psoriasis	1.48e-05	0.000182	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—CYP2S1—psoriasis	1.44e-05	0.000177	CbGpPWpGaD
Tamoxifen—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.4e-05	0.000172	CbGpPWpGaD
Tamoxifen—UGT1A4—Metabolism—PPARG—psoriasis	1.39e-05	0.000171	CbGpPWpGaD
Tamoxifen—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.34e-05	0.000165	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—NDUFA5—psoriasis	1.31e-05	0.000161	CbGpPWpGaD
Tamoxifen—ESR1—Gene Expression—VDR—psoriasis	1.28e-05	0.000157	CbGpPWpGaD
Tamoxifen—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.22e-05	0.00015	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—CARM1—psoriasis	1.19e-05	0.000147	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.18e-05	0.000145	CbGpPWpGaD
Tamoxifen—ABCB11—Metabolism—APOE—psoriasis	1.18e-05	0.000145	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—CARM1—psoriasis	1.17e-05	0.000144	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—CARM1—psoriasis	1.17e-05	0.000143	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism—CAT—psoriasis	1.14e-05	0.000141	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—CYP2S1—psoriasis	1.11e-05	0.000137	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—CARM1—psoriasis	1.1e-05	0.000136	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism—CAT—psoriasis	1.1e-05	0.000135	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.08e-05	0.000133	CbGpPWpGaD
Tamoxifen—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.05e-05	0.000129	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.03e-05	0.000127	CbGpPWpGaD
Tamoxifen—ABCB11—Metabolism—PPARG—psoriasis	1.02e-05	0.000126	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—CARM1—psoriasis	1.01e-05	0.000124	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—CAT—psoriasis	1e-05	0.000123	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—CAT—psoriasis	9.92e-06	0.000122	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.67e-06	0.000119	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.44e-06	0.000116	CbGpPWpGaD
Tamoxifen—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	9.22e-06	0.000113	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—CAT—psoriasis	9.09e-06	0.000112	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—CARM1—psoriasis	9.01e-06	0.000111	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—SOCS1—psoriasis	9e-06	0.000111	CbGpPWpGaD
Tamoxifen—ESR1—Gene Expression—PPARG—psoriasis	8.9e-06	0.00011	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism—APOE—psoriasis	8.87e-06	0.000109	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.82e-06	0.000109	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—CARM1—psoriasis	8.8e-06	0.000108	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism—APOE—psoriasis	8.55e-06	0.000105	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.42e-06	0.000104	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—CARM1—psoriasis	8.29e-06	0.000102	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—CARM1—psoriasis	8.22e-06	0.000101	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—APOE—psoriasis	7.78e-06	9.57e-05	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism—PPARG—psoriasis	7.73e-06	9.51e-05	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—APOE—psoriasis	7.71e-06	9.48e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.68e-06	9.45e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.54e-06	9.27e-05	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism—PPARG—psoriasis	7.44e-06	9.16e-05	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—CAT—psoriasis	7.34e-06	9.03e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—CAT—psoriasis	7.18e-06	8.84e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—CAT—psoriasis	7.17e-06	8.82e-05	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—APOE—psoriasis	7.06e-06	8.69e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—CARM1—psoriasis	7.02e-06	8.64e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—CAT—psoriasis	6.77e-06	8.34e-05	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—PPARG—psoriasis	6.77e-06	8.33e-05	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—PPARG—psoriasis	6.71e-06	8.26e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—LEP—psoriasis	6.64e-06	8.18e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—APOE—psoriasis	6.64e-06	8.18e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.56e-06	8.08e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—CAT—psoriasis	6.21e-06	7.64e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—NFKBIA—psoriasis	6.19e-06	7.62e-05	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—PPARG—psoriasis	6.15e-06	7.57e-05	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—APOE—psoriasis	5.7e-06	7.01e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—APOE—psoriasis	5.58e-06	6.87e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—APOE—psoriasis	5.57e-06	6.86e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—CAT—psoriasis	5.54e-06	6.82e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—CARM1—psoriasis	5.42e-06	6.67e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—CAT—psoriasis	5.41e-06	6.66e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—APOE—psoriasis	5.26e-06	6.48e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—CAT—psoriasis	5.1e-06	6.27e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—TYK2—psoriasis	5.07e-06	6.24e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—CAT—psoriasis	5.05e-06	6.22e-05	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—PPARG—psoriasis	4.96e-06	6.11e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—PPARG—psoriasis	4.86e-06	5.98e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—PPARG—psoriasis	4.85e-06	5.97e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—APOE—psoriasis	4.83e-06	5.94e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—PPARG—psoriasis	4.58e-06	5.64e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—CXCL8—psoriasis	4.41e-06	5.43e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—CAT—psoriasis	4.32e-06	5.32e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—APOE—psoriasis	4.31e-06	5.3e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—APOE—psoriasis	4.2e-06	5.17e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—PPARG—psoriasis	4.2e-06	5.17e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—JUN—psoriasis	4.1e-06	5.05e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—APOE—psoriasis	3.96e-06	4.87e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—NFKB1—psoriasis	3.95e-06	4.86e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—APOE—psoriasis	3.93e-06	4.83e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—PPARG—psoriasis	3.75e-06	4.62e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—PPARG—psoriasis	3.66e-06	4.51e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—VEGFA—psoriasis	3.59e-06	4.41e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—STAT3—psoriasis	3.55e-06	4.37e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—PPARG—psoriasis	3.45e-06	4.25e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—PPARG—psoriasis	3.42e-06	4.21e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—APOE—psoriasis	3.36e-06	4.13e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—CAT—psoriasis	3.33e-06	4.1e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—PPARG—psoriasis	2.92e-06	3.6e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—TP53—psoriasis	2.71e-06	3.33e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—APOE—psoriasis	2.59e-06	3.19e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—IL6—psoriasis	2.48e-06	3.05e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—PPARG—psoriasis	2.26e-06	2.78e-05	CbGpPWpGaD
